Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 13/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100443 | 0.83 | GRM5 (0.46) | GRM5GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL16692498 | 0.82 | JAK2 (0.36) | GRM5GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL18638181 | 0.82 | GRM5 (0.46) | GRM5GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL101660 | 0.76 | GRM4 (0.70) | GRM5GRM4KCNH2HTR2BMTNR1A | |
| SCHEMBL18599488 | 0.73 | GRM5 (0.51) | GRM5 | |
| SCHEMBL5216403 | 0.73 | GRM5 (0.74) | GRM5NOTUMAXL | |
| SCHEMBL12303118 | 0.72 | GRM5 (0.56) | GRM5GRM4KCNH2HTR2BMTNR1A | |
| Trifluoroacetic Acid SCHEMBL4088824 | 0.71 | GRM4 (0.61) | GRM5GRM4 | |
| SCHEMBL16691047 | 0.70 | L3MBTL1 (0.49) | — | |
| SCHEMBL19902102 | 0.70 | GRM5 (0.70) | GRM5NOTUMAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184526-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2348023-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2474545-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2426129-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2455382-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2343299-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2343298-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-05-06 | — | — | EP | disclosed |